8:00 a.m.

NIH Loan Repayment Programs    

Glucose transport in the peripheral tissue

Juleen Zierath, Ph.D. (Karolinska Institute, Stockholm, Sweden)

Session 1: New technologies and insulins for type 1 diabetes

8:50 – 10:25 a.m.

Moderator: Robert A. Vigersky, M.D. (Walter Reed National Military Medical Center, Washington, DC)

Glucose sensor accuracy: What the future holds?

Francine Kaufman, M.D. (Childrens Hospital Los Angeles, Los Angeles, CA)

New pumps for use with open and closed loop systems

Bruce Bode, M.D. (Atanta Diabetes Associates, Atlanta, GA)

Clinical update on the artificial pancreas

Howard Zisser, M.D. (Sansum Diabetes Research Institute, Santa Barbara, CA)

Panel Discussion

10:25 a.m.

Break

Session 2: Major controversies in clinical diabetology

10:45 a.m. – 12:45 p.m.

Moderator: Steven Edelman, M.D. (UCSD, La Jolla, CA)

What are the appropriate glucose targets for people with diabetes?

Irl Hirsch, M.D. (University of Washington Med Ctr-Roosevelt, Seattle, WA)

The pharmacologic treatment of type 2 diabetes: How to decide on what drug when?

Ralph DeFronzo, M.D. (University of Texas Health Science Center, San Antonio, TX)

Diabetes practice guidelines: Whose guidelines should be followed?

Robert A. Vigersky, M.D. (Walter Reed National Military Medical Center, Washington, DC)

New drugs and technologies for diabetes: An FDA point-of-view

Alexander Fleming, M.D. (Kinexum, Harpers Ferry, WV)

Panel Discussion

12:45 p.m.

Break

Session 3: Incretin therapy (inc. Lunch)

1:30 – 3:00 p.m.

Moderator: Irl Hirsch, M.D. (University of Washington Med Ctr-Roosevelt, Seattle, WA)

Looking back at incretin therapy: Has the promise been met?

Jack Leahy, M.D. (University of Vermont, Burlington, VT)

Incretin therapy for type 1 diabetes

Steven Edelman, M.D. (UCSD, La Jolla, CA)

Incretins in the pipeline: What to expect

Carol Wysham, M.D. (Rockwood Main Clinic, Spokane, WA)

Panel Discussion

3:00 p.m.

Closing Remarks